- Home
- IONS
as 11-17-2025 3:42pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 6.8B | IPO Year: | 1991 |
| Target Price: | $80.71 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $76.78 | Next Earning Date: | 10-29-2025 |
| Revenue: | $966,957,000 | Revenue Growth: | 20.41% |
| Revenue Growth (this year): | 27.96% | Revenue Growth (next year): | 2.33% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Birchler Brian | IONS | EVP, Corp and Development Ops | Nov 6 '25 | Sell | $76.17 | 8,000 | $609,379.20 | 48,826 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Nov 6 '25 | Sell | $75.76 | 33,038 | $2,501,724.83 | 59,657 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Nov 5 '25 | Sell | $75.01 | 1,601 | $120,091.01 | 59,657 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Nov 3 '25 | Sell | $75.05 | 1,680 | $126,090.72 | 59,657 | |
| LOSCALZO JOSEPH | IONS | Director | Oct 31 '25 | Sell | $75.10 | 16,000 | $1,201,668.80 | 36,330 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Oct 31 '25 | Sell | $75.11 | 89,249 | $6,703,340.67 | 59,657 | |
| WENDER JOSEPH H | IONS | Director | Oct 31 '25 | Sell | $75.16 | 11,200 | $841,776.32 | 64,035 | |
| WENDER JOSEPH H | IONS | Director | Oct 30 '25 | Sell | $73.07 | 16,800 | $1,230,801.27 | 64,035 | |
| Swayze Eric | IONS | EVP Research | Oct 16 '25 | Sell | $73.62 | 53 | $3,901.93 | 256 | |
| Devers Shannon L. | IONS | EVP, Chief Human Resources Ofc | Oct 16 '25 | Sell | $73.62 | 1,263 | $92,983.70 | 17,494 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Ionis Pharmaceuticals Insider Sold Shares Worth $1,100,385, According to a Recent SEC Filing
MT Newswires
a month ago
Ionis Pharmaceuticals Insider Sold Shares Worth $1,793,744, According to a Recent SEC Filing
MT Newswires
a month ago
Ionis Pharmaceuticals Insider Sold Shares Worth $4,377,054, According to a Recent SEC Filing
MT Newswires
a month ago
Ionis Pharmaceuticals Insider Sold Shares Worth $1,020,210, According to a Recent SEC Filing
Insider Monkey
2 months ago
Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results
Business Wire
2 months ago
Ionis to host investors and analysts for Innovation Day 2025
Simply Wall St.
2 months ago
Ionis Pharmaceuticals (IONS) Is Up 43.6% After Positive Phase 3 Olezarsen Results in Severe Hypertriglyceridemia – Has the Bull Case Changed?
MT Newswires
2 months ago
Ionis Pharmaceuticals Insider Sold Shares Worth $5,396,843, According to a Recent SEC Filing
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.